NCT01208701 (STAD) is a Phase 2 clinical trial of Atorvastatin in Nephropathy, sponsored by Erling Bjerregaard Pedersen.

Who is sponsoring NCT01208701?

NCT01208701 is sponsored by Erling Bjerregaard Pedersen.

What drugs are being tested in NCT01208701?

Interventions in NCT01208701: Atorvastatin, Unikalk.

What condition does NCT01208701 study?

NCT01208701 studies Nephropathy, Cardiovascular Diseases, Diabetes Mellitus.

Is NCT01208701 still recruiting?

NCT01208701 is currently completed. Last updated 19 August 2015.

Last reviewed 2015-08-19 · How we verify

NCT01208701: STAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy

Completed Phase 2 Last updated 19 August 2015

What this trial tests

Phase 2 trial testing Atorvastatin in Nephropathy in 25 participants. Completed in 1 January 2012.

Timeline

1 May 2010

Primary endpoint
1 January 2012

1 January 2012

Quick facts

Lead sponsor	Erling Bjerregaard Pedersen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	25
Start date	1 May 2010
Primary completion	1 January 2012
Estimated completion	1 January 2012
Sites	1 location across Denmark

Drugs / interventions tested

Atorvastatin (atorvastatin) — full drug profile →
Unikalk — full drug profile →

Conditions studied

Nephropathy — all drugs for Nephropathy →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

Erling Bjerregaard Pedersen — full company profile →

Who can join

40 and older, any sex, with Nephropathy or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fractional excretion of sodium
Time frame: 5 days treatment

Sponsor's own description

It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as nephropathy, diabetes and hypertension. The purpose of this study is to investigate the effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular variables in patients with type 2 diabetes with nephropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07462715 — Statins Against Bushfire Smoke · Phase 4 · not yet recruiting
NCT07530289 — A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) · Phase 1 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting

Other recruiting trials for Nephropathy

Currently open trials in the same condition.

NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
NCT06469190 — An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropat · EARLY_PHASE1 · recruiting
NCT05839314 — Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy · Phase 4 · recruiting
NCT06325059 — The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases · NA · recruiting
NCT05656261 — APOL1 Genetic Testing in African Americans · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01208701 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erling Bjerregaard Pedersen
Last refreshed: 19 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01208701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing